ofloxacin ophthalmic / Generic mfg. - LARVOL DELTA

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Jun 2028 | Suspended ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • Cataract • Glaucoma • Ophthalmology

Delayed Inflammatory Reaction to BDDE-Stabilized Hyaluronic Acid Fillers Triggered by Hordeolum in a Diabetic Patient (EADV 2025) - "Materials & A 61-year-old female patient with type 2 diabetes mellitus (treated with metformin 1000 mg/day) received HA filler injections (Croma®) on October 2, 2024, in the zygomatic area, tear troughs, nasolabial folds, chin, and lips...She was treated with oral amoxicillin-clavulanate (1000 mg BID), ofloxacin eye drops, and topical oxytetracycline... The patient was started on systemic clindamycin (300 mg TID) and ciprofloxacin (500 mg BID). Intramuscular dexamethasone 8 mg was administered once daily for three consecutive days, followed by a tapering course of oral prednisolone: 48 mg/day (5 days), 32 mg/day (5 days), 16 mg/day (5 days), and 8 mg/day (5 days)... Delayed inflammatory reactions to HA fillers are likely immune-mediated and may be triggered by systemic events, even months after injection. Although a hordeolum is typically a localized eyelid infection, it may serve as an immune trigger in susceptible individuals. Diabetic status may predispose..."

Clinical • Dermatology • Diabetes • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Ocular Infections • Ophthalmology • Pruritus • Type 2 Diabetes Mellitus

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Suspended | Sponsor: Montefiore Medical Center | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Cataract • Glaucoma • Ophthalmology

An Ocular Manifestation of a Systemic Disease With Encephalitozoon Pogonae in a Juvenile Central Bearded Dragon (Pogona vitticeps). (PubMed, Vet Ophthalmol) - "This case highlights the potential for an ocular manifestation of a systemic disease caused by E. pogonae, underscoring the importance of considering microsporidial infections in the differential diagnosis of refractory ocular disease in reptiles. The findings also emphasize the challenges in diagnosing and treating these infections."

Journal • Cataract • CNS Disorders • Conjunctivitis • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis • Vasculitis

Systemic Envenomation via Ocular Route from a Neurotoxic Snake Venom Ophthalmia--A Case Report. (PubMed, J Acute Med) - "Ofloxacin ophthalmic drops and eye lubrication were prescribed for seven days to minimize complications, and the patient was discharged well after three days of hospitalization. Although difficult to ascertain, signs and symptoms pointed to systemic envenomation, and this could be the first case of an unconventional venom route to date. This paper opens possibilities and serves as precedent for future research - ocular envenomation, snake venom, and blood components, and symptomatic management."

Journal • Ophthalmology • Pain

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis (clinicaltrials.gov) - P2 | N=129 | Completed | Sponsor: IVIEW Therapeutics Inc. | Trial completion date: Oct 2023 ➔ Oct 2024

Trial completion date • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

A case of a child with anterior blepharitis caused by Candida albicans: a case report. (PubMed, J Med Case Rep) - "In this study, we report the clinical findings of a rare case of fungal anterior blepharitis in a Japanese child in which Candida albicans was identified. A noticeable white discharge at the base of the eyelashes and somewhat rapid eyelash loss were characteristic symptoms."

Journal • Cardiovascular • Dry Eye Disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Bowel Disease • Keratitis • Ocular Inflammation • Ophthalmology • Pediatrics • Ulcerative Colitis

Okra eyelid patch versus sodium hyaluronate combined with ofloxacin eye drop in the treatment of meibomian gland dysfunction: a randomized controlled trial (ChiCTR) - P4 | N=40 | Completed | Sponsor: Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University

New P4 trial • Dry Eye Disease • Ophthalmology

Analysis of topical conjunctival microbiotic cultures in patients treated with intravitreal injections using antibiotic prophylaxis with 0.3% ofloxacin eye drops. (PubMed, Int J Retina Vitreous) - "The current results showed that the typical conjunctival bacteria had higher resistance to fluoroquinolones (although they were not tested specifically to ofloxacin), suggesting a possible selection of resistant bacteria that should not be taken for granted in clinic. However, the same bacteria did not exhibit cross-resistance in the analysis of vancomycin and third-generation cephalosporins. This real-world, longitudinal, prospective study on conjunctival flora analyzed bacterial resistance profiles and contemporary antibiotic use, offering deeper insights into this subject."

Journal • Ocular Infections • Ocular Inflammation • Ophthalmology

Glaucoma drainage devices in patients following injector-assisted implantation of an artificial iris into the ciliary sulcus : Video article (PubMed, Ophthalmologie) - "After GDD, dexamethasone eye drops should be applied 8 times daily for 1 week tapering down by 1 drop per week thereafter. Antibiotic eye drops, e.g., ofloxacin eye drops, are prescribed 4 times daily for 1 week and might be discontinued thereafter. To date, this is the first description of a rotation of an artificial iris located in the ciliary sulcus by irrigation of the anterior chamber during GDD implantation."

Journal • Review • Video • Glaucoma • Ophthalmology

Dextenza in the Post-op Management of Vitreoretinal Surgeries (clinicaltrials.gov) - P4 | N=30 | Recruiting | Sponsor: The Cleveland Clinic | Enrolling by invitation ➔ Recruiting | Trial completion date: Jun 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Enrollment status • Surgery • Trial completion date • Trial primary completion date • Inflammation • Ocular Inflammation • Pain

Severe intraocular pressure rise after implantable collamer lens implantation. (PubMed, J Cataract Refract Surg) - "Prednisolone acetate 0.1% ophthalmic suspension eye drops and ofloxacin 0.3% ophthalmic solution eye drops 4 times daily were prescribed prophylactically 2 days preoperatively...The patient was instructed to reduce prednisolone to 2 times a day, discontinue brimonidine, and start brimonidine/timolol (Combigan) 2 times a day and latanoprost at bedtime in both eyes...The patient was instructed to reduce prednisolone to once a day, continue brimonidine/timolol 2 times a day and latanoprost at bedtime, and start acetazolamide (Diamox) 250 mg 2 times a day...What is the most likely mechanism underlying this patient's elevated IOP? What additional diagnostic workup would aid you in making the correct diagnosis?"

Journal • Glaucoma • Ophthalmology • Pain

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Suspended | Sponsor: Montefiore Medical Center | Recruiting ➔ Suspended

Surgery • Trial suspension • Cataract • Glaucoma • Ophthalmology

SUSTAIN: Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery (clinicaltrials.gov) - P4 | N=25 | Terminated | Sponsor: The New York Eye Surgery Center | Completed ➔ Terminated; COVID-19 challenges to recruitment

Surgery • Trial termination • Cataract • Glaucoma • Ophthalmology

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis (clinicaltrials.gov) - P2 | N=129 | Completed | Sponsor: IVIEW Therapeutics Inc. | Not yet recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Oct 2023 | Initiation date: Jun 2023 ➔ Jan 2023 | Trial primary completion date: Dec 2024 ➔ Sep 2023

Trial completion • Trial completion date • Trial initiation date • Trial primary completion date • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

SUSTAIN: Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery (clinicaltrials.gov) - P4 | N=25 | Completed | Sponsor: The New York Eye Surgery Center | Recruiting ➔ Completed | N=40 ➔ 25 | Trial completion date: Dec 2023 ➔ Jul 2023

Enrollment change • Surgery • Trial completion • Trial completion date • Cataract • Glaucoma • Ophthalmology

Case Report of Herpes Zoster Ophthalmicus with Concurrent Parotitis. (PubMed, J Educ Teach Emerg Med) - "The patient was diagnosed with herpes zoster ophthalmicus (HZO) with concurrent ipsilateral parotitis and subsequently treated with valacyclovir, ofloxacin eye drops, topical erythromycin ointment and amoxicillin/clavulanic acid. To our knowledge, this is the first case described in medical literature of a female patient with HZO and ipsilateral parotitis. Herpes zoster opthalmicus, varicella-zoster virus, parotitis."

Journal • Herpes Zoster • Mumps • Ophthalmology • Otorhinolaryngology • Pain • Varicella Zoster • CRP

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Recruiting | Sponsor: Montefiore Medical Center | Suspended ➔ Recruiting | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Enrollment open • Surgery • Trial completion date • Trial primary completion date • Cataract • Glaucoma • Ophthalmology

Acute Iridocyclitis Associated with Intravenous Zoledronic Acid (ENDO 2023) - "She'd had 2 prior outside ED visits for these symptoms and received polymyxin B and later ofloxacin eye drops which did not relieve them...She was discharged with olopatadine eye drops and cetirizine, diagnosed with allergic conjunctivitis, and referred to ophthalmology...Right acute iridocyclitis was diagnosed, she received prednisolone eye drops and cyclopentolate eye drops... ZA-associated ocular inflammation is a rare but serious side effect. This adverse effect has been hypothesized to be associated with increased levels of pro-inflammatory cytokines including Interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-alpha. As with other acute phase reactions to ZA, it does not appear that ocular inflammation tends to recur with subsequent ZA."

Conjunctivitis • Immunology • Musculoskeletal Pain • Ocular Infections • Ocular Inflammation • Oncology • Ophthalmology • Osteoporosis • Pain • Pruritus • Rheumatology • Uveitis • IL6 • TNFA

PAACK: Pilocarpine Use After Kahook Goniotomy (clinicaltrials.gov) - P3 | N=142 | Suspended | Sponsor: Montefiore Medical Center | Enrolling by invitation ➔ Suspended

Surgery • Trial suspension • Cataract • Glaucoma • Ophthalmology

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: IVIEW Therapeutics Inc.

New P2 trial • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology

SUSTAIN: Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: The New York Eye Surgery Center | Trial completion date: Apr 2023 ➔ Dec 2023 | Trial primary completion date: Feb 2023 ➔ Sep 2023

Surgery • Trial completion date • Trial primary completion date • Cataract • Glaucoma • Ophthalmology

Dextenza in the Post-op Management of Vitreoretinal Surgeries (clinicaltrials.gov) - P4 | N=30 | Enrolling by invitation | Sponsor: The Cleveland Clinic | Trial completion date: Jun 2023 ➔ Jun 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Surgery • Trial completion date • Trial primary completion date • Immunology • Inflammation • Ocular Inflammation • Pain

Unilateral vortex keratopathy of unknown etiology. (PubMed, J Cataract Refract Surg) - "Initial examination by the clinician found uncorrected distance visual acuity of 20/100-2 with a corneal abrasion, 4+ corneal edema, and 3+ conjunctival injection, for which he was placed on topical antibiotics (ocuflox and tobradex) with a bandage CL. What would be the most appropriate surgical and/or medical interventions? What would you counsel in prognosis for this patient?"

Journal • Corneal Abrasion • Ophthalmology

Evaluating Adjunctive Cryopreserved Amniotic Membrane Treatment in Herpes Simplex Dendritic Keratitis (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Oregon Health and Science University | N=20 ➔ 0 | Trial completion date: Dec 2021 ➔ Jul 2022 | Recruiting ➔ Withdrawn

Enrollment change • Trial completion date • Trial withdrawal • Herpes Simplex • Keratitis • Ocular Inflammation • Ophthalmology